




The AIDS Clinical Trials Group (ACTG) Network is the largest HIV/AIDS clinical trials organization in the world. We currently have 34 domestic & 25 international sites.



ACTG Network in the News



Dr. Judith Currier Serves as Expert Panelist on *Larry King Now* Discussing HIV Research

Earlier this month, Dr. Judith Currier, ACTG Network Co-Principal Investigator and Professor of Medicine, Chief of Division of Infectious Diseases and Co-Director of the Center for AIDS Research and Education Center at UCLA appeared as a panelist on *Larry King Now*. Dr. Currier joined Jake Glaser, The Elizabeth Glaser Pediatric AIDS Foundation, Christopher Brown, Los Angeles LGBT Center and Sheryl Lee Ralph, Actress and AIDS Activist to discuss "The State of HIV/AIDS

in America."

To watch this informative and thoughtful panel discussion, [click here](#).

ACTG/IMPAACT Networks to Collaborate on Landmark Tuberculosis Study

Protocol A5300B/P2003B: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB)

According to the World Health Organization (WHO), many African countries, including those with DAIDS-funded clinical trial sites have the largest number of new cases of tuberculosis (TB) with 280 per 100,000 persons compared to other populations. People who have TB can infect approximately 10-15 others through close contact over the course of a year without proper treatment. To compound this issue, many people in high burden countries develop TB strains that are resistant to the two primary antibiotics used to treat TB, which is called multidrug-resistant TB (MDR-TB). The condition of MDR-TB is treatable with second-line drugs that are expensive, toxic and less effective than first line drugs. Treatment outcomes for MDR-TB are far worse than for drug susceptible TB and more importantly, there are no evidence based guidelines about how to treat household contacts of patients with MDR-TB. To that end, the ACTG Network has teamed up with the IMPAACT Network to develop Protocol A5300B/P2003B: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB). [Read more>>](#)

OHARA Principal Investigator Advances Study Results

Dr. Jennifer Webster-Cyriaque Teams with DNA Testing Firm to Develop New HPV Diagnostic Biochip

Jennifer Webster-Cyriaque, DDS, PhD, Professor, School of Dentistry and School of Medicine, University of North Carolina, was a key member of the Oral HIV/AIDS Research Alliance (OHARA) which was funded by the National Institute for Dental and Cranial Research (NIDCR) and the National Institute of Allergy and Infectious Disease (NIAID). From 2006 to 2013, OHARA worked in collaboration with the ACTG Network to focus on oral opportunistic infection, including research specifically targeting the Human Papilloma Virus (HPV). In all, there were nine OHARA clinical trials that have contributed to the development of a comprehensive oral infection/disease database with HIV/AIDS correlates. An HIV/AIDS oral specimen bank of over 30,000 aliquots and over 1000 fungal aliquots was also developed and will provide valuable material for future epidemiologic and biological research questions. [Read more>>](#)

ACTG Network Spotlight

Community Representative Serves as Study Participant Voice for REPRIEVE Protocol Team

Meet Paris Mullen

Paris Mullen is one of the dedicated ACTG Network Community Scientific Subcommittee Representatives and Community Advisory Board (CAB) members at our University of Washington, Seattle



Paris Mullen

clinical trial site. Each ACTG Network clinical trial site has a CAB made up of members from the local area that are affected by or living with HIV. The CAB holds regular meetings with site investigators and also hosts events open to the community to educate people about HIV/AIDS and ACTG Network clinical trials. In addition to his duties on the Scientific Subcommittee and CAB, Paris also serves as a designated Community Representative for the REPRIEVE trial. REPRIEVE, a randomized trial to prevent vascular events in HIV, will test whether a daily dose of a statin will reduce the risk of cardiovascular disease among people living with HIV. [Read more>>](#)

World AIDS Day is December 1st



Mark Your Calendars for the 28th Annual World AIDS Day

World AIDS Day is held on December 1st each year and is an opportunity for people worldwide to unite in the fight against HIV/AIDS, show their support for people living with HIV/AIDS and to commemorate those who have passed. The first World AIDS Day took place in 1988 and over the past nearly 28 years it has served to remind the public and Government that HIV/AIDS has not gone away - there is still a vital need to raise money, increase awareness, fight prejudice, improve education and continue research. Government and health officials, non-governmental organizations and individuals around the world observe the day, often providing valuable educational information on HIV/AIDS prevention and control.

For suggestions on how take action to recognize World AIDS Day, [click here](#).

This Month in HIV/AIDS History

October 1983: World Health Organization holds its first meeting to assess the global AIDS situation, and begins international surveillance.

October 1986: U.S. Surgeon General, C. Everett Koop, issues the **Surgeon General's Report on AIDS**. The report urges parents and schools to start frank, open discussions about AIDS and urges education and condom use.

October 1998: ACT UP protests at FDA headquarters about the drug-approval process.

Eight days later, FDA announces new regulations to speed up drug approvals.

October 2009: President Obama announces his administration will officially lift the HIV travel and immigration ban in January 2010 by removing the final regulatory barriers to entry.

Source: AIDS.gov



Thank you for taking the time to read the ACTG Network's Monthly Newsletter. If you would like to be a guest blogger, have your clinical trial site highlighted or would like to nominate a colleague for the Spotlight, please [click here](#). We welcome your feedback.

Sincerely,

Patrick Bayhille

Senior Research Communications Specialist

AIDS Clinical Trials Group Network

[VISIT OUR WEBSITE](#)



Like us on Facebook

Follow us on [twitter](#)

Copyright © 2015. All Rights Reserved.